What is Sidoti Csr's Forecast for Balchem FY2025 Earnings?

Key Points

• Sidoti Csr analysts have raised their FY2025 earnings per share (EPS) estimate for Balchem Corporation to $5.20, reflecting an increase from their previous estimate of $5.15.
• Balchem recently reported a quarterly EPS of $1.27, surpassing consensus estimates, with revenues of $255.47 million, a 9.1% increase year-over-year.
• Institutional investors hold a significant stake in Balchem, comprising 87.91% of the company's stock, with various firms increasing their positions in recent quarters.

Balchem Corporation (NASDAQ:BCPC - Free Report) - Equities researchers at Sidoti Csr increased their FY2025 earnings per share estimates for shares of Balchem in a note issued to investors on Monday, August 4th. Sidoti Csr analyst D. Harriman now expects that the basic materials company will post earnings of $5.20 per share for the year, up from their previous forecast of $5.15. The consensus estimate for Balchem's current full-year earnings is $4.64 per share. Sidoti Csr also issued estimates for Balchem's Q4 2025 earnings at $1.35 EPS, Q1 2026 earnings at $1.31 EPS, Q2 2026 earnings at $1.42 EPS, Q4 2026 earnings at $1.38 EPS and FY2026 earnings at $5.50 EPS.

Balchem (NASDAQ:BCPC - Get Free Report) last posted its earnings results on Thursday, July 31st. The basic materials company reported $1.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.25 by $0.02. The company had revenue of $255.47 million during the quarter, compared to the consensus estimate of $250.31 million. Balchem had a net margin of 14.48% and a return on equity of 12.41%. The firm's quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.09 earnings per share.

A number of other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Balchem from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. HC Wainwright reaffirmed a "buy" rating and issued a $189.00 price objective (up previously from $180.00) on shares of Balchem in a report on Monday.

Balchem Stock Performance

Balchem stock traded up $3.58 during midday trading on Tuesday, hitting $160.00. 165,364 shares of the company were exchanged, compared to its average volume of 192,143. Balchem has a fifty-two week low of $145.70 and a fifty-two week high of $185.96. The firm has a market capitalization of $5.19 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 3.34 and a beta of 0.88. The business has a fifty day simple moving average of $159.43 and a two-hundred day simple moving average of $162.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.57 and a current ratio of 2.64.

Institutional Investors Weigh In On Balchem

A number of institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of Balchem during the first quarter worth $1,148,000. GAMMA Investing LLC boosted its holdings in shares of Balchem by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 1,068 shares of the basic materials company's stock worth $177,000 after purchasing an additional 196 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of Balchem by 243.2% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,390 shares of the basic materials company's stock valued at $1,559,000 after purchasing an additional 6,654 shares in the last quarter. Sowell Financial Services LLC acquired a new stake in shares of Balchem in the first quarter valued at approximately $202,000. Finally, KBC Group NV lifted its position in Balchem by 24.1% during the first quarter. KBC Group NV now owns 1,582 shares of the basic materials company's stock worth $263,000 after buying an additional 307 shares in the last quarter. Institutional investors and hedge funds own 87.91% of the company's stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.